

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 5

Complete if Known

Application Number	10/788,489
Filing Date	March 1, 2004
First Named Inventor	Serge CARILLO
Art Unit	1633
Examiner Name	Scott LONG
Attorney Docket Number	ST94037BUS/80375.003

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO/92/21373	12/1992	Logothetou-Rella		
		EP 159 678	10/39/1985	Sakurai et al.		
		EP 395 309	10/31/1990	Asada et al.		
		WO93/02106	02/04/1993	Nixon, et al.		
		EP 569 122	11/10/1993	Omura, et al.		
		EP 580 161	01/26/1994	Saito, et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND COMMUNICATIONS TO: U.S. PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8189 (1-800-786-8189) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sh

2

of 5

Complete if Known

10/300 480

10788,489

March 1, 2004

Serge C

1633

Scott LONG

Attorney Docket Number ST94037BUS/80375.0033

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 94/21817	09/29/1994	Henkart, et al.		
		WO 00/21575	04/20/2000	Atencio		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
(For general assistance in completing the form, call 1-800-RTO-9199 (1-800-786-9199) and select option 2.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/788,489
				Filing Date	March 1, 2004
				First Named Inventor	Serge CARILLO
				Art Unit	1633
				Examiner Name	Scott LONG
Sheet	3	of	5	Attorney Docket Number	ST94037B/80375.0033

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		Y. EMORI et al. All Four Repeating Domains of the Endogenous Inhibitor for Calcium-dependent Protease Independently Retain Inhibitory Activity, J. Biol Chem 263:2364-2370;1988		
		H. WITSCHI et al. "Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor, Carcinogenesis 10:2275-2277 (1989)		
		W. TROLLI et al. "Protease Inhibitors as Anticarcinogens, JNCI 73 (6):1245-1250		
		M. OHKOSHI (1980) Gann 71: 246-250		
		CARILLO et al., "Differential sensitivity of FOS and JUN family members to calpains", Oncogene 9, 1679-1689 (1994)		
		LEVRERO et al., "Defective and Nondefective Adenovirus Vectors for Expression Foreign Genes in Vitro and In Vivo", Gene, 101, 195-202, (1991)		
		MAKI et al., "Inhibition of Calpain by a Synthetic Oligopeptide Corresponding to an Exon of the Human Calpastain Gene" Journal of Biol. Chemistry, 254, (32), 18866-18869 1989		
		OHKOSHI, "Effect of Aprotinin On Growth of 3-Methylcholanthrene-Induced Squamous Cell Carcinoma in Mice", Gann 71: 246-250 (1980)		
		ORKIN, et al., "Report & Recommendations of the Panel to Assess The NIH Investment In Research On Gene Therapy", NIH, 1-20 (12/1995)		
		DACH, et al. "Targeting gene therapy to cancer: A Review", ONCOLOGY rES., Vol. 9: 313-325, 1997		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/788,489
				Filing Date	March 1, 2004
				First Named Inventor	Serge CARILLO
				Art Unit	1633
				Examiner Name	Scott LONG
Sheet	4	of	5	Attorney Docket Number	ST94037B/80375.0033

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VERMA et al., "Gene therapy-promises, problems and prospects", Nature, Vol. 389: 239-242 (9/1997)	
		DEONARAIN, MP., "Ligand-targeted receptor-mediated vectors for gene delivery." Exp. Opin. Ther. Patents, Vol. 8(1): 53-69 (1998).	
		ECK et al., "Gene-based therapy", Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Nith Edition: 77-101. (1996).	
		ASADA et al., "cDNA cloning of human calpastain; sequence homology among human, pig, and rabbit calpastatins" J. Enzym. Inhib., Vol. 3(1): 49-56 (1989)	
		BISCHOFF et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells." Science, Vol. 274:373-376. (10/1996)	
		MILLER et al., "Target vectors for gene therapy", FASEB, Vol. 9: 190-199 (2/1995)	
		CRYSTAL, RG., "Transfer of Genes to Humans: Early lessons and obstacles to success", Science, Vol. 270: 404-410. (1995)	
		MARSHALL, "Gene Therapy's Growing Pains", Science, Vol. 269:1050-1055 (1995)	
		ANDERSON, W. French, "Nature Medicine, Vol. 6 No. 8, page 862 (8/2000)	
		WAGENKNECHT, et al., "Proteasome Inhibitors Induces p53/p21-Independent Apoptosis in Human Glioma Cells", Cell Physiol Biochem (1999); 9:117-125	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/788,489
				Filing Date	March 1, 2004
				First Named Inventor	Serge CARILLO
				Art Unit	1633
				Examiner Name	Scott LONG
Sheet	5	of	5	Attorney Docket Number	ST94037B/80375.0033

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		AN, et al., "Protease inhibitor-induced apoptosis: accumulation of wp p53, p51 WAF1/CIP1, and induction of apoptosis are independent...", Luekemia (2000) 14:1276-1283		
		KUBBUTAT, et al., "Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of protein Stability", Molecular and Cellular Biology, (1/1997); pgs. 46-468		
		KUBBUTAT, et al., "Keeping an old friend under control: regulation of p53 stability", Molecular Medicine Today (6/1998): pgs. 250-256		
		ATENCIO, et al., "Celpain Inhibitor 1 Activates p53-dependent Apoptosis in Tumor Cell Lines", Cell Growth & Differentiation, 5/200: Vol. 11, pgs. 247-253		
		PARIAT, et al., "Proteolysis by Calpains: a Possible Contribution to Degradation of p53", Molecular and Cellular Biology, (5/1997): Vol. 17(5): pgs. 2806-2815		
		CARAFOLI, et al., "Breakthroughs and Views Calpain: A Protease in Search of a Function?", Biochemical and Biophysical Research Communications 247:193-203 (1998)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.